CMS Open Payments · Program Year 2024
Limacorporate S.p.A.
Limacorporate S.p.A. reported $343,583.69 across General Payments, Research, and Ownership to 119 physicians and teaching hospitals across 161 transactions.
- $343.6K Above-median payer
- All-tracks total
- 161 Above-median volume
- Transactions
- 119 Below-median reach
- Recipients
- −$151.0K
- General Payments vs PY2023
Limacorporate S.p.A. reported $343,583.69 across all CMS Open Payments tracks (General + Research + Ownership) to 119 physicians and teaching hospitals in Program Year 2024 - ranking #861 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $183,821.45, averaging $2.9K per recipient.
How Limacorporate S.p.A.'s $343.6K all-tracks total breaks down
Limacorporate S.p.A.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
13/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer limacorporate-s-p-a Limacorporate S.p.A.
$343.6K · #861/1,925 · 0.0% industry · PY2024
- TOT $343.6K
- RANK #861
- SHARE 0.0%
- TXN 161
- RCP 119
- CAT 4
- GEN $183.8K
- ΔGEN −$151.0K
- TOP1 18.9%
- PY 2024
Volume peers
Nearest volume peer: Carl Zeiss Meditec AG ($341.0K)
Limacorporate S.p.A. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Limacorporate S.p.A.'s CMS-reported General Payments decreased by $151.0K (−45.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: LIMACORPORATE S.P.A.PY2023: LIMACORPORATE S.P.A.PY2024: Limacorporate S.p.A.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $334,823.23
- PY2024
- $183,821.45
What the Data Shows for Limacorporate S.p.A.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Limacorporate S.p.A., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $123.7K, accounting for 67.3% of this company's General Payments and 60 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads Limacorporate S.p.A.'s 4-category general-payment breakdown at $123.7K, 67.3% of the reported total.
Limacorporate S.p.A. reports 4 general-payment categories - the top three are Consulting Fee (67.3%), Royalty or License (19.9%), and Travel and Lodging (11.8%). The remaining 1 category make up 1.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Limacorporate S.p.A. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $123.7K | 60 | 67.3% |
| Royalty or License | $36.6K | 4 | 19.9% |
| Travel and Lodging | $21.7K | 27 | 11.8% |
| Food and Beverage | $1.8K | 28 | 1.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $107,285.97 (58.4%) of $183,821.45 in this company's General Payments records across 28 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Limacorporate S.p.A.
The five named recipients with the highest reported General Payments from this company
- 1
Benjamin Stronach
$34,755.10 across 8 reported transactions
- 2
Seth Greenky
$25,000.00 across 8 reported transactions
- 3
Patrick Connor
$16,661.47 across 2 reported transactions
- 4
Anil Dutta
$15,594.40 across 15 reported transactions
- 5
Craig Cummins
$15,275.00 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Limacorporate S.p.A.'s spend rank (#861 of 1,925, top 45% by spend) and concentration rank (#1,032 of 1,838, bottom 44% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Spectrum Pharmaceuticals Inc. : $38.7K total payments, HHI 1008
- Orthalign Inc : $1.5M total payments, HHI 1006
- Canon Medical Informatics, Inc. : $35.2K total payments, HHI 1001
- Ortho Systems : $2.4K total payments, HHI 1000
- TruAbutment Inc. : $204.0K total payments, HHI 999
- Treace Medical Concepts, Inc. : $10.0M total payments, HHI 997
- Limacorporate S.p.A. (this company) : $183.8K total payments, HHI 995
- CLR Medical, Inc. : $10.8K total payments, HHI 991
- Tactile Systems Technology Inc : $810.5K total payments, HHI 989
- Vivus LLC : $184.4K total payments, HHI 986
- Geron Corporation : $91.2K total payments, HHI 985
- Macrogenics, Inc. : $1.1K total payments, HHI 985
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Limacorporate S.p.A.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Limacorporate S.p.A..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Limacorporate S.p.A..
Showing 6 of 1,924 companies with CMS-reported payment data.
Phadia US Inc.
Bernhard Foerster GmbH
ALK-Abello, Inc
UCB Biosciences Inc.
Noven Pharmaceuticals, Inc.
Put this to use
Limacorporate S.p.A. ranks #861 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Limacorporate S.p.A.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.